Ibio inc (IBIO) - News Archive

Revolutionizing Muscle Regeneration: iBio s Groundbreaking Advances in Anti-Myostatin Antibody Therapy The biotechnology landscape is on the cusp of a significant evolution, heralded by promising advancements from iBio,...

: iBio Inc. has announced an expansion of its cardiometabolic and obesity program through the development of a novel bispecific antibody targeting Myostatin and Activin A, building upon the success of its existing anti-...

In recent developments, prominent biopharmaceutical company iBio Inc. has closed the sale of its manufacturing facility located in Texas. This transaction has successfully eliminated approximately $13.2 million of secur...

The fight against obesity and cardiometabolic diseases continues to present significant challenges for the healthcare industry. However, a beacon of hope arises as two leading innovators, iBio and AstralBio, join forces...

iBio Announces Successful $15.0 Million Private Placement with Significant Premium to Last CloseiBio, a leading biologics contract manufacturing organization, has recently announced a successful private placement offeri...

iBio, Inc. (NYSEA:IBIO), a leading biotech company specialized in the development and manufacturing of biotherapeutics, has recently declared a 20-to-1 reverse stock split of its common stock. The decision, which receiv...